Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Eosinophilic Esophagitis Clinical Trial Pipeline Analysis of 15+ Companies by DelveInsight

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

25 Jul, 2022, 15:30 GMT

Share this article

Share toX

Share this article

Share toX

Eosinophilic esophagitis (EoE) is a chronic disorder of the digestive system in which large numbers of a particular type of white blood cell called eosinophils are present in the esophagus. Key players operating in the global eosinophilic esophagitis market include Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline, AstraZeneca, Allakos, and others

LAS VEGAS, July 25, 2022 /PRNewswire/ -- DelveInsight's 'Eosinophilic Esophagitis Pipeline Insight 2022' report provides comprehensive global coverage of available, marketed, and pipeline eosinophilic esophagitis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the eosinophilic esophagitis pipeline domain.

Key Takeaways from the Eosinophilic Esophagitis Pipeline Report

  • DelveInsight's eosinophilic esophagitis pipeline report depicts a robust space with 15+ active players working to develop 15 + pipeline therapies for eosinophilic esophagitis treatment. 
  • Leading eosinophilic esophagitis companies such as Sanofi/Regeneron, AstraZeneca, Bristol Myers Squibb, Ellodi Pharmaceuticals, Allakos, EsoCap AG, Arena Pharmaceuticals, GlaxoSmithKline, Landos Biopharma, Calypso Biotech, DBV Technologies, Celldex Therapeutics, NexEos Bio, Aqilion,  Quorum Innovations, Serpin Pharma, RAPT Therapeutics and others are evaluating novel eosinophilic esophagitis treatment drugs candidate to improve the treatment landscape.
  • Key eosinophilic esophagitis pipeline therapies in various stages of development includes Dupilumab, Benralizumab, CC-93538, APT-1011, AK002, ESO-101, Etrasimod, Mepolizumab, CALY-002, BT-11, Barzolvolimab,  NDX33-o, SP16, Qi-201, Esomeprazole ODT, IRL201104, and others.
  • In March 2022, Pfizer Inc. announced the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases.  Arena Pharmaceuticals brings to Pfizer a portfolio of diverse and promising development-stage therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator currently in development for a range of immuno-inflammatory diseases including ulcerative colitis, Crohn's Disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata.
  • Etrasimod is an oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator being investigated for a range of immuno-inflammatory diseases including ulcerative colitis, Crohn's Disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata. In June 2021, the US FDA granted Orphan Drug designation to etrasimod for treating eosinophilic esophagitis. Currently, it is being investigated in the Phase II stage of development.
  • Lirentelimab (AK002), being developed by Allakos, targets Siglec-8, an inhibitory receptor found on the surface of mast cells and eosinophils. In the completed Phase II ENIGMA study, patients who had concomitant EoE showed esophageal eosinophil reduction and had less difficulty swallowing when treated with lirentelimab. Allakos has initiated a Phase III randomized, double-blind, placebo-controlled study of lirentelimab in patients with EoE.
  • The US FDA has cleared Landos Pharma's Investigational New Drug (IND) application for omilancor (BT-11), a novel, orally administered, gut-restricted LANCL2 agonist in development for the treatment of Eosinophilic Esophagitis (EoE). The company expects to initiate a randomized, double-blind, placebo-controlled Phase Ib study designed to evaluate the safety and pharmacokinetics of omilancor in patients with active Eosinophilic Esophagitis

Request a sample and discover the recent advances in eosinophilic esophagitis treatment @ Eosinophilic Esophagitis Pipeline Outlook

The eosinophilic esophagitis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage eosinophilic esophagitis products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the eosinophilic esophagitis pipeline landscape.

Eosinophilic Esophagitis Overview

Eosinophilic esophagitis (EoE) is a chronic, immune-mediated/allergen-mediated clinicopathological disease. Clinically, it is distinguished by signs of esophageal dysfunction. EoE's chronic inflammation causes eosinophilic esophagitis symptoms. However, the exact eosinophilic esophagitis causes are not known.

Early detection and eosinophilic esophagitis treatment are critical to preventing the progression of fibrotic abnormalities in the esophagus, which may be only partially reversible. For eosinophilic esophagitis diagnosis, an upper endoscopy including biopsies of the esophagus is required. Currently, eosinophilic esophagitis treatment includes dietary elimination diets, off-label usage of proton pump inhibitors, and glucocorticoid steroid formulations.

Find out more about eosinophilic esophagitis treatment @ Eosinophilic Esophagitis Treatment Guidelines

A snapshot of the Eosinophilic Esophagitis Pipeline Drugs mentioned in the report:

Drugs

Company

Phase 

MoA

RoA

APT-1011

Ellodi Pharma

Phase III

Glucocorticoid receptor agonists

Oral

CC-93538

Celgene Corporation

Phase III

Interleukin 13 inhibitors

Subcutaneous

AK002

Allakos

Phase III

Antibody-dependent cell cytotoxicity; Immunomodulators; Mast cell inhibitors

Subcutaneous

Benralizumab

AstraZeneca

Phase III

Antibody-dependent cell cytotoxicity; Apoptosis stimulants

Subcutaneous

IRL201104

Revolo Biotherapeutics

Phase II

Immunomodulators

Intravenous

ESO-101

EsoCap AG

Phase II

Glucocorticoid receptor agonists

Oral

CALY-002

Calypso Biotech

Phase I

Interleukin 15 inhibitors

Intravenous

Barzolvolimab

Celldex Therapeutics

Phase I

Proto oncogene protein c-kit inhibitors

Subcutaneous

Learn more about the novel and emerging eosinophilic esophagitis pipeline therapies @ Eosinophilic Esophagitis Clinical Trials

Eosinophilic Esophagitis Therapeutics Assessment

The eosinophilic esophagitis pipeline report proffers an integral view of the eosinophilic esophagitis emerging novel therapies segmented by stage, product type,  molecule type,  mechanism of action, and route of administration.

Scope of the Eosinophilic Esophagitis Pipeline Report 

  • Coverage: Global 
  • Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical
  • Therapeutics Assessment By Molecule Type: Monoclonal antibody, Peptides, Polymer, Small molecule, Gene therapy
  • Therapeutics Assessment By Mechanism of Action: Glucocorticoid receptor agonists, Interleukin 13 inhibitors, Interleukin 15 inhibitors, Antibody-dependent cell cytotoxicity, Apoptosis stimulants, Immunomodulators, Mast cell inhibitors, Immunomodulators, Proto oncogene protein c-kit inhibitors
  • Key Eosinophilic Esophagitis Companies: Sanofi/Regeneron, AstraZeneca, Bristol Myers Squibb, Ellodi Pharmaceuticals, Allakos, EsoCap AG, Arena Pharmaceuticals, GlaxoSmithKline, Landos Biopharma, Calypso Biotech, DBV Technologies, Celldex Therapeutics, NexEos Bio, Aqilion,  Quorum Innovations, Serpin Pharma, RAPT Therapeutics, and others
  • Key Eosinophilic Esophagitis Pipeline Therapies: Dupilumab, Benralizumab, CC-93538, APT-1011, AK002, ESO-101, Etrasimod, Mepolizumab, CALY-002, BT-11, Barzolvolimab,  NDX33-o, SP16, Qi-201, Esomeprazole ODT, IRL201104, and others.

Dive deep into rich insights for drugs for eosinophilic esophagitis, visit @ New Drug for Eosinophilic Esophagitis Treatment 

Table of Contents

1.

Eosinophilic Esophagitis Pipeline Report Introduction

2.

Eosinophilic Esophagitis Pipeline Report Executive Summary

3.

Eosinophilic Esophagitis Pipeline: Overview

4.

Analytical Perspective In-depth Commercial Assessment

5.

Eosinophilic Esophagitis Pipeline Therapeutics

6.

Eosinophilic Esophagitis Pipeline: Late Stage Products (Pre-registration)

7.

Eosinophilic Esophagitis Pipeline: Late Stage Products (Phase III)

7.1

APT-1011: Ellodi Pharma

8.

Eosinophilic Esophagitis Pipeline: Mid Stage Products (Phase II)

8.1

IRL201104: Revolvo Biotherapeutics

9.

Eosinophilic Esophagitis Pipeline: Early Stage Products (Phase I)

9.1

CALY-002: Calypso Biotech

10.

Eosinophilic Esophagitis Pipeline Therapeutic Assessment

11.

Inactive Products in the Eosinophilic Esophagitis Pipeline

12.

Company-University Collaborations (Licensing/Partnering) Analysis

13.

Key Companies

14.

Key Products in the Eosinophilic Esophagitis Pipeline

15.

Unmet Needs

16.

Market Drivers and Barriers

17.

Future Perspectives and Conclusion

18.

Analyst Views

19.

Appendix

For further information on the eosinophilic esophagitis pipeline therapeutics, reach out @ Drugs for Eosinophilic Esophagitis

Related Reports

Eosinophilic Esophagitis Market

Eosinophilic Esophagitis Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key eosinophilic esophagitis companies including Sanofi, Regeneron, AstraZeneca, Bristol Myers Squibb, among others.

Eosinophilic Esophagitis Epidemiology Forecast

Eosinophilic Esophagitis Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical and forecasted eosinophilic esophagitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Eosinophilic Gastroenteritis Market

Eosinophilic Gastroenteritis Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key eosinophilic gastroenteritis companies including Allakos, AstraZeneca, among others.

Eosinophilic Gastroenteritis Epidemiology Forecast

Eosinophilic Gastroenteritis Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical and forecasted eosinophilic gastroenteritis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Eosinophilic Disorder Pipeline

Eosinophilic Disorder Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key eosinophilic disorder companies, including Children's Hospital Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases, among others.

Eosinophilic Disorder Market

Eosinophilic Disorder Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key eosinophilic disorder companies including Children's Hospital Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases, among others.

Other Trending Reports

Persistent Depressive Disorder Market | Gene Therapy for Ocular Rare Disease Market | Congestive Heart Failure Market | CRISPR Therapies Pipeline | Desmoplastic Small Round Cell Tumors Market | India Healthcare Outlook Report | Psychosis Market | Dental Lasers Market | Primary Immune Deficiency Market I Dyslipidemia Market | Lateral Epicondylitis Disease Market | Castration-Resistant Prostate Cancer Market | Metrorrhagia Market | Global Messenger RNA-based Vaccines and Therapeutics Market | Negative Pressure Wound Therapy Systems Market | US Healthcare Outlook Report | Mucinous Cystic Neoplasms Market | Hot Flashes Market | Varicose Veins - Market | Hemostats Market | Injectable Drug Delivery Devices Market | Breast Pumps Market | Physiotherapy Equipment Market | Trastuzumab Biosimilars Insight | Deep Brain Stimulation Devices Market | Retinoblastoma Market | Venous Stenosis Market | Tumor Ablation Market | Substance Abuse Market | Insulin Glargine Biosimilar Insight | Interspinous Spacers Market | Anti-hypertension Market

Latest Healthcare Blogs

Genital Warts Treatment Market

Vaccines Market Outlook

Top Cardiac Devices For Heart Disease Prevention

Burn Treatment Landscape

Chlamydia Treatment

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. 

Connect with us at LinkedIn 

Contact Us

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

Modal title

Also from this source

Cancer Cachexia Market Anticipates Impressive Growth Trajectory at a CAGR of 8.9% During the Forecast Period (2025-2034) | DelveInsight

Cancer Cachexia Market Anticipates Impressive Growth Trajectory at a CAGR of 8.9% During the Forecast Period (2025-2034) | DelveInsight

DelveInsight's Cancer Cachexia Market Insights report includes a comprehensive understanding of current treatment practices, cancer cachexia emerging ...

Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology | DelveInsight

Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology | DelveInsight

DelveInsight's Bispecifics/BiTE Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding ...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.